Nicardipine: A Hypotensive Dihydropyridine-Type Calcium Antagonist with a Peculiar Cerebrovascular Profile

References

• Takenaka T, Usuda S, Nomura T, Maeno H, Sado T. Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4(3-nitrophenyl)-1,4 dihydropyridine-3,5dicarboxilic acid 3-(2-N-benzyl-N-methylamino)-ethyl ester 5-methyl ester hydrochloride (YC-93). Arznm Forsch. 1976; 26: 2172–2178
   PubMed Web of Science ®Google Scholar
• Iwanami M, Shibanuma T, Fujimoto M, Kawai R, Tamazawa K, Takenaka T, Takahashi K, Murakami M. Synthesis of new water-soluble dihydropyridine vasodilators. Chem Pharm Bull (Tokyo). 1979; 27: 1426–1440
   PubMed Web of Science ®Google Scholar
• Takenaka T, Handa J. Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients. Int J Clin Pharmacol Biopharm. 1979; 17: 1–23
   PubMedGoogle Scholar
• Takenaka T, Asano M, Shiono K, Shibasaki M, Inagaki O. Cardiovascular pharmacology of nicardipine in animals. Br J Clin Pharmacol. 1985; 20(Suppl. 1)7S–22S
   PubMedGoogle Scholar
• Otomo E. Clinical effects of YC-93 (nicardipine hydrochloride) in patients with various cerebrovascular diseases. Clin Rep. 1979; 13: 1207–1213
   Google Scholar
• Yamada T, Muroga T, Kimura J. Tourniquet-induced ischemia and somatosensory evoked potentials. Neurology. 1981; 31: 1524–1529
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Terai M, Takenaka T, Maeno H. Inhibition of cyclic AMP phosphodiesterase by 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)] ethyl ester 5-methyl ester hydrochloride (YC-93), a potent vasodilator. Biochem Pharmacol. 1978; 27: 1269–1274
   PubMed Web of Science ®Google Scholar
• Satoh K, Yanagisawa T, Taira N. Mechanisms underlying the cardiovascular action of a new dihydopyridine vasodilator, YC-93 (nicardipine). Clin Exp Pharmacol Physiol. 1980; 7: 249–262
   PubMed Web of Science ®Google Scholar
• Terai M, Takenaka T, Maeno H. Inhibition of calcium influx in rabbit aorta by nicardipine hydrochloride (YC-93). Biochem Pharmacol. 1981; 30: 375–378
   PubMed Web of Science ®Google Scholar
• Casteels R, Droogmans G. Exchange characteristics of the noradrenaline-sensitive calcium store in vascular smooth muscle cells or rabbit ear artery. J Physiol. 1981; 317: 263–279
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Ohta T, Noburo T. Mechanism of relaxant actions of nicardipine, a new calcium antagonist, on isolated dog cerebral and mesenteric arteries. Stroke. 1983; 14: 270–275
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Kuryama H. Effects of agents that modulate potassium permeability on smooth muscle cells of the guinea-pig basilar artery. Br J Pharmacol. 1983; 79: 23–35
   PubMed Web of Science ®Google Scholar
• Struyker-Boudier HAJ, Smits JFM, De Mey JGR. The pharmacology of calcium antagonists: A review. J Cardiovasc Pharmacol. 1990; 15(Suppl. 4)S1–S10
   PubMedGoogle Scholar
• Hofman F, Nastainezyk W, Rohrkasten A, et al. Regulation of the L-type calcium channel. Trends Pharmacol Sci. 1987; 8: 393–398
   Web of Science ®Google Scholar
• Freedman DD, Waters DD. Second generation dihydropyridine calcium antagonists: Greater vascular selectivity and some unique applications. Drugs. 1997; 34: 578–598
   Google Scholar
• Amenta F, Ferrante F, Sabbatini M, Ricci A. Quantitative image analysis study of the cerebral vasodilatory activity of nicardipine in spontaneously hypertensive rats. Clin Exper Hypertens A. 1994; 16: 359–371
   Google Scholar
• Karashima T, Kuriyama H. Electrical properties of smooth muscle cell membrane and neuromuscular transmission in the guinea-pig basilar artery. Br J Pharmacol. 1981; 74: 495–504
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fujiwara S. Neurogenic electrical response of single smooth muscle cells of the dog middle cerebral artery. Circ Res. 1982; 51: 751–759
   PubMed Web of Science ®Google Scholar
• Uski TK, Andersson KE. Effect of prostanoids on isolated feline cerebral arteries, II: Roles of extra- and intracellular calcium for the prostaglandin F2α-induced contraction. Acta Physiol Scand. 1984; 120: 197–205
   PubMedGoogle Scholar
• Wendling WW, Harakal C. Comparative action of pentobarbital and verapamil on canine cerebral and pheripheral arteries in vitro. Res Commun Chem Pathol Pharmacol 1985; 49: 189–202
   PubMedGoogle Scholar
• Sasaki T, Kassel NF, Zuccarello M. Dependence of cerebral arterial contractions on intracellulary stored calcium. Stroke. 1986; 17: 95–97
   PubMed Web of Science ®Google Scholar
• Salomon JB, Torregrosa G, Miranda FJ, Alabadì JA, Alvarez C, Alborch E. Calcium entry blockers inhibit prostaglandin F2α-induced cerebrovascular contractile response in goats. Eur J Pharmacol 1991; 203: 33–39
   PubMed Web of Science ®Google Scholar
• Alborch E, Salomon JB, Perales AJ, Torregrosa G, Miranda FJ. Alabadì JA, Jover T. Comparison of the anticonstrictor action of dihydropyridines (nimodipine and nicardipine) and Mg2+ in isolated human cerebral arteries. Eur J Pharmacol. 1992; 229: 83–89
   PubMed Web of Science ®Google Scholar
• Brading AF. Maintenance of ionic composition. Br Med Bull. 1979; 35: 227–234
   PubMed Web of Science ®Google Scholar
• Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: A reassessment and a hypothesis. Am J Physiol. 1981; 294: 752–761
   Google Scholar
• Okada T, Shibuya M, Suzuki Y, Ikegaki I, Kageyama N, Asano T, Hidaka H. Effect of the intracellular calcium antagonist HA1004 on cerebral blood flow in rats. Neurol Med Chir (Jap). 1988; 28: 625–630
   PubMedGoogle Scholar
• Grotta J, Spydell J, Pettigrew C, Ostrow P, Hunter D. The effect of nicardipine on neuronal function following ischemia. Stroke. 1986; 17: 213–219
   PubMed Web of Science ®Google Scholar
• Hadani M, Young W, Flamm ES. Nicardipine reduces calcium accumulation and electrolyte derangement in regional ischemia in rats. Stroke. 1988; 19: 1125–1132
   PubMed Web of Science ®Google Scholar
• Whiting RL. Animal pharmacology of nicardipine and its clinical relevance. Am J Cardiol. 1987; 59: 3J–9J
   PubMed Web of Science ®Google Scholar
• Alps BJ, Calder C, Hass WK, Wilson AD. Comparative protective effect of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the mongolian gerbil. Br J Pharmacol. 1988; 93: 877–883
   PubMed Web of Science ®Google Scholar
• Sakabe T, Nagai I, Ishikawa T, Takeshita H, Masuda T, Matsumoto M, Tateishi A. Nicardipine increases cerebral blood flow but does not improve neurologic recovery in a canine model of complete cerebral ischemia. J Cer Blood Flow Metab. 1986; 6: 684–690
   PubMed Web of Science ®Google Scholar
• Dote K. Cerebral hemodynamics of post-ischemic delayed hypoperfusion (PDH) and the effects of nicardipine on the PDH. Jpn J Anesthesiol. 1990; 39: 357–366
   PubMedGoogle Scholar
• Iwatsuki N, Ono K, Takahashi M, Tajima T. The effect of nicardipine given after 10 minutes complete global cerebral ischemia on neurologic recovery. J Anesth (Jap). 1990; 4: 337–342
   PubMedGoogle Scholar
• Kucharczyk J, Chew W, Derugin N, Moseley M, Rollin C, Berry I, Norman D. Nicardipine reduces ischemic brain injury. Stroke. 1989; 20: 268–274
   PubMed Web of Science ®Google Scholar
• Montero JL, Grau M, Balasch J. Nicardipine: Protection against brain hypoxia. Drugs Exp Clin Res. 1986; 12: 377–380
   PubMedGoogle Scholar
• Grotta J, Pettigrew C, Rosenbaum D, Reid C, Rhoades H, McCandless D. Efficacy and mechanism of action of a calcium channel blocker after global cerebral ischemia in rats. Stroke. 1988; 17: 447–454
   Google Scholar
• Grotta JC, Picone CM, Dedman JR, Rhoades HM, Strong RA, Earls RM, Yao LP. Neuronal protection correlates with prevention of calcium-calmodulin binding in rats. Stroke. 1990; 21(Suppl. 3), III-28–III-31
   Google Scholar
• Abe K. Effect of nicardipine hydrochloride on ischemic brain edema. Neurol Med Chir (Jap). 1987; 27: 819–824
   PubMedGoogle Scholar
• Ricci A, Sabbatini M, Tomassoni D, Mignini F, Petrelli C, Amenta F. Neuronal populations of rat cerebral cortex and hippocampus expressed a higher density of L-type calcium channel than corresponding cerebral vessels. Clin Exp Hypertens. 2002; 24: 715–726
   PubMed Web of Science ®Google Scholar
• Schmidt-Kastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 1991; 40: 599–636
   PubMed Web of Science ®Google Scholar
• Alps BJ, Calder C, Wilson AD. The effect of nicardipine on “delayed neuronal death” in the ischaemic gerbil hippocampus. Br J Pharmacol Proc. Suppl. 1986; 88: 250
   Google Scholar
• Hewitt K, Corbett D. Combined treatment with MK-801 and nicardipine reduced global ischemic damage in the gerbil. Stroke. 1992; 23: 82–86
   PubMed Web of Science ®Google Scholar
• Asano T, Ikegaki I, Satoh S, Mochizuki D, Hidaka H, Suzuki Y, Shibuya M, Sugita K. Blockade of intracellular actions of calcium may protect against ischemic damage to the gerbil brain. Br J Pharmacol. 1991; 103: 1935–1938
   PubMed Web of Science ®Google Scholar
• Nagaoka A. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. J Hypertens. 1986; 4(Suppl)S523–S525
   Google Scholar
• Suzuki S. Influence of duration of antihypertensive treatment on experimental cerebral ischemia in SHRSR. Nippon Ika Daigaku Zasshi 1987; 54: 118––127
   PubMedGoogle Scholar
• Suzuki S, Katayama Y, Memezawa H, Sugimoto S, Nagazumi A, Terashi A. Influence of long-term antihypertensive treatment on cerebral ischemia induced by bilateral carotid ligation in stroke-prone spontaneously hypertensive rats. Protective effect of nicardipine hydrochloride. Med Consult New Remed (Jap). 1987; 24: 1043–1046
   Google Scholar
• Amenta F, Strocchi P, Sabbatini M. Vascular and neuronal hypertensive brain damage: Protective effect of treatment with nicardipine. J Hypertens. 1996; 14(Suppl)S29–S35
   Google Scholar
• Sabbatini M, Bellagamba G, Casado A, Tayebati SK, Venarucci D, Amenta F. Protective effect of treatment with nicardipine on cerebrovascular tree of spontaneously hypertensive rats. Clin Exp Hypertens. 2001a; 23: 143–155
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Bellagamba G, Vega JA, Amenta F. Effect of antihypertensive treatment on peripheral nerve vasculature in spontaneously hypertensive rats. Clin Exp Hypertens. 2001; 23: 157–66
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Mignini F, Venarucci D, Vega JA, Amenta F. Effect of nicardipine treatment on the expression of neurofilament 200 KDa immunoreactivity in the brain of spontaneously hypertensive rats. Clin Exp Hypertens. 2001; 23: 127–141
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin Exp Hypertens. 2002; 24: 727–740
   PubMed Web of Science ®Google Scholar
• Tomassoni D, Mancinelli G, Mignini F, Sabbatini M, Amenta F. Quantitative image analysis of choroid and retinal vasculature in SHR: A model of cerebrovascular hypertensive changes?. Clin Exp Hypertens. 2002; 24: 741–752
   PubMed Web of Science ®Google Scholar
• Kaplan JA. Clinical considerations for the use of intravenous nicardipine in the treatment of postoperative hypertension. Am Heart J. 1990; 119: 443–446
   PubMed Web of Science ®Google Scholar
• Pepine CJ. Intravenous nicardipine: Cardiovascular effects and clinical relevance. Clin Ther. 1988; 10: 316–325
   PubMedGoogle Scholar
• Cluzel P, Chatellier G, Rivalan J, et al. Predictive factors of the blood pressure fall induced by intravenous nicardipine. J Cardiovasc Pharm. 1989; 13: 370–375
   PubMed Web of Science ®Google Scholar
• Escande M, David D, Diadema B. Effets antihypertenseurs de la nicardipine intraveineuse dans 1'hypertension arterielle du sujet age. Therapie. 1989; 44: 161–165
   PubMedGoogle Scholar
• Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol. 1989; 64: 8H–15H
   PubMed Web of Science ®Google Scholar
• Ryman KS, Kubo SH, Shaknovich A, et al. Influence of baseline hemodynamic status and sympathetic activity on the response to nicardipine, a new dihydropyridine, in patients with hypertension or chronic congestive heart failure. Clin Pharmacol Ther. 1987; 41: 483–489
   PubMed Web of Science ®Google Scholar
• Silke B, Hafizullah M, Frais MA, et al. Haemodynamic effects of nicardipine in acute myocardial infarction. Postgrad Med J. 1984; 60: 29–34
   PubMed Web of Science ®Google Scholar
• Sorkin EM, Clissold SP. Nicardipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987; 33: 296–345
   PubMed Web of Science ®Google Scholar
• Fischell TA, Maheshwari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol. 2004; 16: 428–432
   PubMedGoogle Scholar
• Curran MP, Robinson DM, Keating GM. Intravenous nicardipine: Its use in the short-term treatment of hypertension and various other indications. Drugs. 2006; 66: 1755–1782
   PubMed Web of Science ®Google Scholar
• Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006; 8: 357–373
   PubMedGoogle Scholar
• Lambert CR, Pepine CJ. Acute antianginal hemodynamic effects of nicardipine in coronary artery disease. American Heart Journal. 1990; 119: 457–462
   PubMed Web of Science ®Google Scholar
• Lambert CR, Pepine CJ. Critical drug appraisal: Nicardipine. Drug Therapy. 1990; 20: 55–61
   Google Scholar
• Broadhurst PA, Brigden G, Heber M, et al. Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nicardipine. Cardiovascular Drugs and Therapy. 1990; 4: 435–438
   PubMed Web of Science ®Google Scholar
• Palatini P, Businaro R, Racioppa A, et al. The effect of slow-release nicardipine on 24-hour blood pressure and blood pressure response to exercise. Curr Ther Res. 1990; 47: 759–764
   Web of Science ®Google Scholar
• Sega R, Centonze F, Borgnino C, et al. Repeated 24-hour ambulatory blood pressure rnonitoring of essential hypertensives during long-term treatment with slow-release nicardipine. Curr Ther Res. 1988; 43: 1053–1062
   Web of Science ®Google Scholar
• Maetzel FK, Teufel WE, Griebel A, Glocke MH. Double-blind, randomized comparative study of the antihypertensive effect of nicardipine slow-release and nifedipine slow-release in hypertensive patients with coronary heart disease. Cardiovasc Drug Ther. 1991; 5: 647–654
   PubMed Web of Science ®Google Scholar
• Cavatorta A, Pucci F, Ghirarduzzi A, et al. Sustained-release nicardipine corrects hypertension and cardiac hypertrophy in renal insufficiency. Curr Ther Res. 1990; 48: 298–307
   Web of Science ®Google Scholar
• Dessi-Fulgheri P, Di Noto G, Catalina R, et al. Effects of slow-release nicardipine on blood pressure, diuresis, and atrial natriuretic factor in hypertensives. Curr Ther Res. 1990; 48: 395–402
   Web of Science ®Google Scholar
• Herpin D. Cerveau et hypertension artèrielle. Première partie. Aspects physiologique et physiopathologique. Ann Cardiol Angiol. 1989; 38: 269–272
   PubMedGoogle Scholar
• Mazzola C, Borgnino C, Colombo D, et al. Antihypertensive and hemodynamic effects of slow-release nicardipine. Int J Clin Pharmacol Ther Toxic. 1988; 26: 503–508
   PubMedGoogle Scholar
• Stornello M, Valvo EV, Scapellato L. Effect of sustained-release nicardipine, chlorthalidone, and the two drugs combined in patients with mild to moderate hypertension. Curr Ther Res. 1990; 47: 405–411
   Web of Science ®Google Scholar
• Forette F, McClaran J, Hervy MP, et al. Nicardipine in elderly patients with hypertension: A review of experience in France. Am Heart J. 1989; 117: 256–261
   PubMed Web of Science ®Google Scholar
• Krakoff LR. Nicardipine monotherapy in ambulatory elderly patients with hypertension. Am Heart J. 1989; 117: 250–255
   PubMed Web of Science ®Google Scholar
• Leonetti G. The clinical performance of nicardipine in elderly hypertensive patients with concomitant disease. Am Heart J. 1989; 117: 266–269
   PubMed Web of Science ®Google Scholar
• Littler WA. Nicardipine in the elderly hypertensive: A review of experience in the United Kingdom. Am Heart J. 1989; 117: 262–265
   PubMed Web of Science ®Google Scholar
• Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data. J Neurol Sci. 2002; 204: 147–151
   Google Scholar
• Sabbatini M, Strocchi P, Amenta F. Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-disorders. Clin Exp Hypertens. 1995; 17: 719–750
   PubMed Web of Science ®Google Scholar
• Gaab MR, Czech T, Korn A. Intracranial effects of nicardipine. Br J Clin Pharmacol. 1985; 20: 67S–74S
   PubMed Web of Science ®Google Scholar
• Martì Masso JF, Lozano R. Nicardipine in the prevention of cerebral infarction. Clin Ther. 1990; 12: 344–351
   PubMed Web of Science ®Google Scholar
• Lozano R, Balaguer A. Nicardipine in the treatment of outpatients with cerebrovascular disorders. Clin Ther. 1991; 13: 496–499
   PubMed Web of Science ®Google Scholar
• Ribas Mundò M, Lozano R. The influence of nicardipine in patients with high risk of stroke. J Cardiovasc Pharmacol. 1990; 16(Suppl. 2)S16–S19
   PubMedGoogle Scholar
• Otomo E, Tsuru M, Kutsuzawa T, Kogure H, Terashi A, Tazaki Y, Araki G, Ito E, Sekimoto H, Omae T, Sawada T, Kito S, Fuzishima M, Goto F. The clinical efficacy of Bay-e-9736 for the treatment of cerebrovascular disorders. Geriatr Med (Jap). 1986; 24: 1–81
   Google Scholar
• Nishikawa T, Omote K, Namiki A, Takahashi T. The effect of nicardipine on cerebrospinal fluid pressure in humans. Anesth Analg 1986; 65: 507–510
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Hitoshi F, Kurehara K, Yamada M. Effects of nicardipine on cerebral vascular responses to hypocapnia and blood flow velocity in the middle cerebral artery. Stroke. 1991; 22: 1170–1172
   PubMed Web of Science ®Google Scholar
• Yoshinaga S, Kimura M, Tanaka T, Ueno Y, Tanaka A. Effects of oral administration of nicardipine on cerebral blood flow in hypertensive patients. Diagnosis Treatment (Jap). 1991; 79(Suppl)2686–2690
   Google Scholar
• Flamm ES, Adams HP, Beck DW, Pinto RS, Marler JR, Walker MD, Godersky JC, Loftus CM, Biller J, Boarini DJ, O'Dell C, Banwart K, Kongable G. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Nerosurg. 1988; 68: 393–400
   PubMed Web of Science ®Google Scholar
• Montarry M, Chacornac R, Philippon B, Bouchet CI, Guichard P. Effects of an intravenous injection of nicardipine on cerebral blood flow in subarachnoid hemorrhage caused by intracranial aneurysm. Agressologie. 1989; 30: 411–415
   PubMedGoogle Scholar
• Combes P, Fauvage B. Systemic vasomotor interaction between nicardipine and hypocapnic alkalosis in man. Intensive Care Med. 1992; 18: 89–92
   PubMed Web of Science ®Google Scholar
• Beck DW, Adams HP, Flamm ES, Godersky JC, Loftus CM. Combination of aminocaproic acid and nicardipine in treatment of aneurysmal subarachnoid hemorrhage. Stroke. 1988; 19: 63–67
   PubMed Web of Science ®Google Scholar
• Fujita K, Yamashita H, Masamura M, Ehara K, Tamaki N, Matsumoto S. The effects of ticlopidine and nicardipine on the prevention of symptomatic vasospasm after aneurysmal rupture. No Shinkei Geka (Jap). 1988; 16: 741–746
   PubMedGoogle Scholar
• Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2000; 2, CD000277
   Google Scholar
• Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: Analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery. 2005; 56: 895–902
   PubMed Web of Science ®Google Scholar
• Barth M, Capelle HH, Weidauer S, Weiss C, Munch E, Thome C, Luecke T, Schmiedek P, Kasuya H, Vajkoczy P. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: A prospective, randomized, double-blind phase IIa study. Stroke. 2007; 38: 330–336
   PubMed Web of Science ®Google Scholar
• Medical Reseach Council Working Party. Stroke and coronary heart disease in mild hypertension: Risk factors and the value of treatment. Br Med J 1988; 296: 1565–1570
   PubMed Web of Science ®Google Scholar
• Barry DI, Vorstrup S, Jarden JO, Svendsen UG, Braendstrup O, Graham DI, Strandgaard S. Effects of antihypertensive drugs on the cerebral circulation. Acta Med Scand. 1993; 677(Suppl)143–147
   Google Scholar
• Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res. 2005; 17: 16–30
   PubMedGoogle Scholar
• Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, Porcellati C. Calcium channel blockade to prevent stroke in hypertension: A meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004; 17: 817–822
   PubMed Web of Science ®Google Scholar
• Yao L.P, Ding D.Y. Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral infarction. J Neurol Neurosurg Psychiat 1990; 53: 844–846
   PubMed Web of Science ®Google Scholar
• Rosenbaum DM, Zabramski J, Frey J, Yatsu F, Marler L, Spetzler R, Grotta J. Early treatment of ischemic stroke with a calcium antagonist. Stroke. 1991; 22: 437–441
   PubMed Web of Science ®Google Scholar
• Lisk DR, Grotta GC, Lamki LM, Tran HD, Taylor JW, Molony DA, Barron BJ. Should hypertension be treated after acute stroke?. Arch Neurol. 1993; 50: 855–862
   PubMed Web of Science ®Google Scholar
• Uematsu D, Watanabe S, Katayama T. Nicardipine improves cerebral hemodynamics in acute and subacute stroke. Neurology. 1992; 42(4 Suppl. 3)395
   Google Scholar
• Gamèz NM, Soto Mas JA, Aguilar Martinez JL, Bermùdez Garcia JM, Salim A, Ramos Jimènez A, Gil Extremera B. Ensayo clìnico controlado a doble ciego: Nicardipina frente a placebo en la isquemia cerebral focal aguda. Med Clin (Barc). 1988; 90: 690–692
   PubMedGoogle Scholar
• Rosenbaum DM, Grotta JC, Yatsu FK, Picone CM, Pettigrew LC, Bratina P, Zabramski J, Spetzler R, Lopez L, Marler J, Ellis D. A pilot study of nicardipine for acute ischemic stroke. The nicardipine study group. Cerebral ischemia and calcium, A Hartmann, W Kuschinsky. Springer, Berlin 1989; 367–372
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–1187
   PubMed Web of Science ®Google Scholar
• Handa J, Matsuda M, Nakasu Y, Nakasu S, Kidooka M, Watanbe K. Clinical effect of a new 1,4-dihydropyridine derivative, YC-93, in patients with cerebrovascular diseases. Arch Jpn Chir. 1979; 48: 400–403
   PubMedGoogle Scholar
• Miyamoto T. Effect of long-term treatment with YC-93 (Nicardipine HCl), a 1,4,-dihydropyridine derivative, on obstructive cerebrovascular disorders. Clin Rep (Jap). 1981; 15: 426–434
   Google Scholar
• Saku J. Clinical use of YC-93 (Nicardipine HCl) in patients with cerebrovascular disorders, part 2: Long-term use of YC-93. Clin Rep (Jap). 1981; 15: 233–242
   Google Scholar
• Tajika Y. Clinical study of nicardipine hydrochloride (Perdipine) in patients with cerebral vascular disorders. Basic Clin Med (Jap). 1982; 16: 315–318
   Google Scholar
• Tamura M. Clinical efficacy of nicardipine hydrochloride for the treatment of various cerebrovascular disorders. Clin Rep (Jap). 1982; 16: 257–262
   Google Scholar
• Hiramine T. Clinical effects of nicardipine hydrochloride (Perdipine) on cerebrovascular disorders. Med Consult New Remed (Jap). 1983; 20: 97–102
   Google Scholar
• Kuriyama Y, Sawada T, Niimi T, Naritomi H, Kinugawa H, Fukushima M, Kaneko T. Effects of nicardipine and nifedipine on cerebral circulation in cerebrovascular disorders. J Cereb Blood Flow Met. 1983; 3(Suppl. 1)560–561
   Google Scholar
• Iijima K. Effects of perdipine on post-apoplectic disorders and cerebral arteriosclerosis. Clin Rep (Jap). 1983; 17: 153–162
   Google Scholar
• Ikeda T. Clinical trial of YC-93 (Nicardipine HCl) in patients with cerebral vascular disorders and cerebral blood flow disturbances. Clin Rep (Jap). 1983; 17: 263–277
   Google Scholar
• Iwabuchi S. Effects and safety of nicardipine hydrochloride in patients with higher cerebral dysfunction. Med Consult New Remed (Jap). 1987; 24: 169, .
   Google Scholar
• De Cabo JP. Estudio clìnico de un derivado piridìnico nitrofenilado, la nicardipina, como agente vasodilatator cerebral. Rev Esp Geriatr Gerontol. 1984; 19: 311–315
   Google Scholar
• Vintrò Molins C, Viaplana Màs JM. Ensayo clìnico a doble ciego parallelo de nicardipina frente a placebo en pacientes con insuficiencia vascular cerebral crònica. Med Clin (Barc). 1985; 84: 308–311
   PubMedGoogle Scholar
• Gonzàles-Elipe J, Romero J, Lozano R. Nicardipine in the treatment of the cerebral ischemic attack sequelae: Double-blind study versus placebo. International Symposium on Calcium Antagonists; 1987, New York
   Google Scholar
• Spanish Group of Nicardipine Study in Vascular Dementia. An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia. Rev Neurol. 1999; 15: 28, 835–845
   Google Scholar
• Gonzalez-Gonzalez JA, Lozano RA. Study of the tolerability and effectiveness of nicardipine retard in cognitive deterioration of vascular origin. Rev Neurol. 2000; 30: 719–728
   PubMed Web of Science ®Google Scholar
• De Fabritiis A, Pili C, Scondotto G, Borgatti E. Modificazioni delle resistenze vascolari cerebrali valutate mediante tecnica del doppler carotideo: effetti della nicardipina verso cinnarizina. Giorn It Angiol. 1985; 5: 41–59
   Google Scholar
• Puccinelli F, Pieraccini F, Tomei GP, Gargiulo L. L' ipertensione arteriosa nella fase riabilitativa dell' ictus cerebrale. Clin Ter. 1989; 130: 29–35
   PubMedGoogle Scholar
• Scarzella L, Bergamasco B. La nicardipina nella terapia dell' ipertensione arteriosa dell' anziano affetto da sindrome psico-organica. Clin Ter. 1989; 130: 171–178
   PubMedGoogle Scholar
• Weir B. Calcium antagonist, cerebral ischemia and vasospasm. Can J Neurol Sci. 1984; 11: 239–246
   PubMed Web of Science ®Google Scholar
• Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002, CD000147
   Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in vascular dementia. Expert Opin Pharmacother 2004; 5: 1399–1410
   PubMed Web of Science ®Google Scholar
• Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D. Efficacy and safety of nimodipine in subcortical vascular dementia: A randomized placebo-controlled trial. Stroke. 2005; 36: 619–624
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 1011–1053
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252
   PubMed Web of Science ®Google Scholar
• Birkenhäger WH, Staessen JA. Progress in cardiovascular diseases: Cognitive function in essential hypertension. Prog Cardiovasc Dis. 2006; 49: 1–10
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352: 1347–1351
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007; 117: 3393–3402
   PubMed Web of Science ®Google Scholar